[1]Majo,VattolyJ.;Arango,Victoria;Simpson,NormanR.;Prabhakaran,Jaya;Kassir,SuhamA.;Underwood,MarkD.;Bakalian,Mihran;Canoll,Peter;JohnMann;DileepKumar[BioorganicandMedicinalChemistryLetters,2013,vol.23,#14,p.4191-4194]
[2]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2008/9497,2008,A1Locationinpatent:Page/Pagecolumn51
[1]Wittman,MarkD.;Carboni,JoanM.;Yang,Zheng;Lee,FrancisY.;Antman,Melissa;Attar,Ricardo;Balimane,Praveen;Chang,Chiehying;Chen,Cliff;Discenza,Lorell;Frennesson,David;Gottardis,MarcoM.;Greer,Ann;Hurlburt,Warren;Johnson,Walter;Langley,DavidR.;Li,Aixin;Li,Jianqing;Liu,Peiying;Mastalerz,Harold;Mathur,Arvind;Menard,Krista;Patel,Karishma;Sack,John;Sang,Xiaopeng;Saulnier,Mark;Smith,Daniel;Stefanski,Kevin;Trainor,George;Velaparthi,Upender;Zhang,Guifen;Zimmermann,Kurt;Vyas,DolatraiM.[JournalofMedicinalChemistry,2009,vol.52,#23,p.7360-7363]
[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2008/9497,2008,A1
[2]Majo,VattolyJ.;Arango,Victoria;Simpson,NormanR.;Prabhakaran,Jaya;Kassir,SuhamA.;Underwood,MarkD.;Bakalian,Mihran;Canoll,Peter;JohnMann;DileepKumar[BioorganicandMedicinalChemistryLetters,2013,vol.23,#14,p.4191-4194]
[1]Patent:US2008/9497,2008,A1
[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2008/9497,2008,A1
[2]Majo,VattolyJ.;Arango,Victoria;Simpson,NormanR.;Prabhakaran,Jaya;Kassir,SuhamA.;Underwood,MarkD.;Bakalian,Mihran;Canoll,Peter;JohnMann;DileepKumar[BioorganicandMedicinalChemistryLetters,2013,vol.23,#14,p.4191-4194]
Title: CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Journal: Cancer research 20140715
Title: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
Journal: Pancreas 20130401
Title: IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
Journal: Experimental hematology 20120901
Title: Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Journal: Cancer research 20111215
Title: High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110415
Title: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Journal: Endocrine-related cancer 20100901
Title: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.
Journal: Bioorganic & medicinal chemistry letters 20100901
Title: LC-MS/MS method using unbonded silica column and aqueous/methanol mobile phase for the simultaneous quantification of a drug candidate and co-administered metformin in rat plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601
Title: Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Journal: Journal of medicinal chemistry 20091210
Title: BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
Journal: Molecular cancer therapeutics 20091201
Title: Carboni JM, et al. BMS-754807, a small molecule inhibitor of IGF-1R/IR. Mol Cancer Ther, 2009, 8(12), 3341-3349.
Title: Franks SE, et al. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes. 2016 Mar 1;9:134.
Title: Wittman MD, et al. Discovery of a 2,4-disubstituted pyrrolo,2-f,2,4triazine inhibitor (BMS-754807) of IGF-1R kinase in clinical development. J Med Chem, 2009, 52(23), 7360-7363.
Title: Kolb EA, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer, 2011, 56(4), 595-603.
